Physician profile
Christopher Hatae
NPI 1194977306
$3,819.82
in general payments reported to CMS, 2019-2025
11 companies · $25.72 in 2025
The $25.72 reported for 2025 was less than what a typical General Practice (Dentist) provider received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $438 · 2021: $2,895 · 2022: $49.77 · 2023: $30.76 · 2024: $78.84 · 2025: $25.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Straumann USA LLC | $1,779.00 | 2019-2021 | |
| Dentsply Sirona INC | $652.75 | 2019-2021 | |
| Patterson Companies, INC. | $602.50 | 2021 | |
| Voco America INC. | $386.59 | 2020-2023 | Voco Retraction Paste, Admira Protect, Voco Profluorid Varnish |
| Ivoclar Vivadent, INC. | $180.00 | 2019 | |
| A-Dec, INC. | $78.84 | 2024 | |
| Kuraray America INC. | $49.77 | 2022 | |
| Nobel Biocare USA | $31.77 | 2019 | |
| Zimvie INC. | $25.72 | 2025 | |
| Biolase, INC. | $18.61 | 2023 | Waterlase Iplus |
| 3m Company | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hatae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.